Lixivaptan (American Home Products).
Lixivaptan is a non-peptide, orally-active vasopressin antagonist under development by American Home Products for the potential treatment of hyponatremia associated with diseases such as heart failure, liver cirrhosis and nephrotic syndrome. By 1997, it was in phase II trials in the US and elsewhere for hyponatremia [2424051. It selectively prevents vasopressin-dependent water resorption, increasing water excretion with low electrolyte loss [266993] and is selective towards the human V2 versus V1 receptors [295987].
Martinez-Castelao
A
A
Hospital Bellvitge CSUB, University of Barcelona, Spain. 9349amc@webcmb.comb.es
D000818:Animals; D001381:Azepines / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy*; D011758:Pyrroles; D013329:Structure-Activity Relationship; D014667:Vasopressins / Q000037:antagonists & inhibitors*; D001569:Benzodiazepines
D001381:Azepines; D001549:Benzamides; D011758:Pyrroles; D014667:Vasopressins; C409452:lixivaptan; D001569:Benzodiazepines